ERS 2014: GSK reports positive Phase III results of its mepolizumab in asthma

8 September 2014

UK pharma major GlaxoSmithKline (LSE: GSK) has reported positive data from its Phase III asthma studies of mepolizumab, an investigational interleukin (IL)-5 antagonist monoclonal antibody.

The drug met its primary endpoints in two studies. The first was a statistically significant reduction in the frequency of clinically significant asthma exacerbations compared to placebo, and the second was a statistically significant reduction of daily oral corticosteroid dose during weeks 20-24 compared to the dose determined during the optimization phase of the trial. The data were presented at the European Respiratory Society (ERS) Congress.

Treatment with mepolizumab also gave improved quality of life and improved asthma control.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK